Thymosin α-1
Thymosin Alpha-1 (Zadaxin)
Immune modulator and T-cell support
About
A 28-amino-acid peptide that regulates T-cell maturation. FDA approved in 35+ countries (as Zadaxin) for hepatitis B and as an adjuvant in cancer therapy. Key in immune response.
Mechanism
Boosts Th1 response, activates dendritic cells and NK cells, balances cytokine production.
Dosage
Draw to 16 units on a U-100 insulin syringe
10 mg · 1 mL BAC
When to take: Timing matters little — morning or evening is fine.
Reconstitution
Vial size (mg): 10 mg · BAC water (mL): 1 mL · Concentration: 10 mg/mL
Very stable peptide. Tolerates freezing after reconstitution (unlike many others).
Dosing reference
Units to draw at the typical dose range, per vial size.
| Vial | Water | Typical draw |
|---|---|---|
| 10 mg | 1 mL | 30–80 units |
Benefits
- Strengthens the immune system (especially T cells)
- Helps with chronic viral infections
- Adjuvant in cancer therapy
- Very safe for long-term use
- Improves wound healing via immune mediation
Side effects
- Very well tolerated
- Rare: injection-site irritation
- Rare: mild fatigue in the first weeks
Gender notes
Cautions
- Autoimmune disease (caution — may increase immune activity)
- Organ transplantation (immunosuppression required)
- Pregnancy (limited data)
Research
- Camerini & Garaci: Historical review of Thymosin α1
Annals of the New York Academy of Sciences · 2015
Review of 40 years of use: immune support, cancer, infections.
- Liu et al: Thymosin alpha-1 in chronic HBV
Hepatology International · 2020
Meta-analysis of 23 trials, effective for HBV clearance.